Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2023-08-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the fifth Supervisory Board of Ruikang Medical Group Co., Ltd. It includes approval of a guarantee limit proposal and the 2023 semi-annual report and its summary. The document states that the semi-annual report has been reviewed and approved by the Supervisory Board and will be submitted to the third extraordinary general meeting of shareholders for approval. The document is short (1353 characters) and primarily serves as a notice of the meeting resolutions and the approval of the interim report, rather than containing the full interim report itself. Therefore, it is an announcement related to the interim report, not the report itself. According to the rules, such announcements are best classified as Regulatory Filings (RNS) because it does not contain substantive financial data or the full report text but announces the approval and submission of the interim report.
2023-08-29 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "瑞康医药集团股份有限公司2023 年半年度报告全文" which translates to "Realcan Pharmaceutical Group Co., Ltd. 2023 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2023 to June 30, 2023. The content includes detailed financial data, management discussion and analysis, business segment performance, and other comprehensive financial and operational information typical of an interim or quarterly report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-29 Chinese
关于累计诉讼情况的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by 瑞康医药集团股份有限公司 regarding the cumulative litigation and arbitration cases involving the company and its subsidiaries over the past twelve months. It includes detailed statistics on the number of cases, amounts involved, and the potential impact on the company's profits. The document references compliance with Shenzhen Stock Exchange listing rules and provides a table summarizing the litigation cases. The document is relatively short (3240 characters) and serves as a disclosure of legal proceedings rather than a full legal report or audit. It does not contain financial statements or detailed management analysis but focuses on legal matters and their impact on the company. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2023-08-29 Chinese
半年报董事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the fifth board of directors' third meeting of Ruikang Pharmaceutical Group Co., Ltd. It includes decisions on guarantees, appointment of board secretary and vice president, approval of the 2023 semi-annual report and its summary, and the proposal to convene the 2023 third extraordinary shareholders' meeting. The document does not contain the full semi-annual report itself but mentions that the report was reviewed and approved. The document length is short (2395 characters) and primarily serves as a formal announcement of board meeting resolutions rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain substantive financial data or the full report.
2023-08-29 Chinese
关于召开2023年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening a 2023 third extraordinary general meeting of shareholders for 瑞康医药集团股份有限公司. It includes information about the meeting time, location, voting procedures (both onsite and online), eligibility to attend, agenda items, and proxy authorization forms. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and instructions for the shareholders' meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-08-29 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2023 by 瑞康医药集团股份有限公司. It contains specific financial data such as beginning balances, transaction amounts, interest, repayments, and ending balances for various related parties and subsidiaries. The document is 7893 characters long, which is substantial and contains actual financial data rather than just an announcement or certification. The content is focused on financial transactions and balances for a half-year period, indicating it is a financial report related to interim or quarterly reporting. There is no indication that this is an annual report, audit report, or earnings release. The detailed financial data for a half-year period aligns with the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.